Gestational Trophoblastic Tumor (GTN): Causes, Staging, and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Gestational trophoblastic disease (GTD) is a spectrum of proliferative conditions of the trophoblast — the cells that normally form the placenta — arising from an abnormal pregnancy. The spectrum ranges from the premalignant hydatidiform mole (complete or partial) through to gestational trophoblastic neoplasia (GTN), which includes invasive mole, choriocarcinoma, placental site trophoblastic tumor (PSTT), and epithelioid trophoblastic tumor (ETT). GTN can arise after any type of pregnancy — normal delivery, miscarriage, ectopic pregnancy, or molar pregnancy. Choriocarcinoma is the most malignant form, with a propensity for early hematogenous metastasis (particularly to the lungs, liver, and brain), yet it remains one of the most chemosensitive solid tumors in oncology. Gestational trophoblastic neoplasia has an overall cure rate exceeding 95% — even metastatic choriocarcinoma is curable in most patients with appropriate chemotherapy — making it a landmark example of successful oncological management. The exquisitely sensitive biomarker beta-HCG (human chorionic gonadotropin) enables accurate diagnosis, treatment response monitoring, and surveillance.

Hydatidiform moles — the most common precursor to GTN — result from abnormal fertilization events. Complete hydatidiform moles arise from fertilization of an enucleate (empty) oocyte by one or two sperm, resulting in a diploid androgenetic genome (46,XX or 46,XY) — all genetic material is paternal, and there is no fetal development. Partial moles arise from fertilization of a normal oocyte by two sperm (diandric triploidy, 69,XXX or 69,XXY), producing some fetal tissue alongside trophoblastic proliferation. Risk factors for hydatidiform mole include extremes of maternal age (teenagers and women over 40 have the highest risk), prior molar pregnancy (recurrence risk 1–2% after one mole, rising to ~25% after two moles), and Asian ethnicity. After suction evacuation of a mole, GTN develops in approximately 15–20% of complete moles and 0.5–5% of partial moles. GTN after non-molar pregnancies (choriocarcinoma after term delivery, miscarriage, or ectopic pregnancy) is rarer but clinically important to recognize. Gestational choriocarcinoma — not to be confused with non-gestational (gonadal) choriocarcinoma — is an exclusively gestational malignancy with a very favorable response to chemotherapy.

Hydatidiform mole presents in the first trimester with vaginal bleeding (most common symptom), uterine size larger than expected for gestational age, markedly elevated serum beta-HCG (often exceeding 100,000 IU/L in complete moles), hyperemesis gravidarum (severe vomiting from high HCG levels), and — with complete moles — absent fetal cardiac activity on ultrasound. Snowstorm ultrasound pattern (multiple vesicular echoes, no fetus, no amniotic fluid) is characteristic of complete moles. GTN after molar evacuation or other pregnancy may present as: persistent or rising beta-HCG after expected normalization; irregular vaginal bleeding; newly palpable uterine mass; hemoptysis or dyspnea (from pulmonary metastases); headache, seizures, or focal neurological signs (from cerebral metastases — a medical emergency requiring urgent management); or intraperitoneal hemorrhage from uterine perforation. PSTT and ETT are rare subtypes that produce less HCG, may present years after the antecedent pregnancy, and are generally less chemosensitive than choriocarcinoma. Any woman of reproductive age with unexplained hemoptysis, neurological symptoms, or elevated HCG without a current pregnancy should be evaluated for GTN.

Diagnosis and staging follow the FIGO 2000 staging system combined with the FIGO risk score. Diagnosis of GTN is made in the setting of an antecedent pregnancy (molar or non-molar) and a rising or persistently elevated beta-HCG meeting defined criteria, even without tissue biopsy — GTN is one of the few cancers where treatment can be initiated on biochemical criteria alone. After molar evacuation, GTN is diagnosed if beta-HCG: rises ≥10% over 3 measurements over 2 weeks, plateaus (±10%) over 4 or more measurements over 3 weeks, remains elevated beyond 6 months (complete mole) or 8 weeks (partial mole), or if there is histological evidence of invasive mole or choriocarcinoma. Workup includes chest X-ray or CT thorax (pulmonary metastases — most common site), CT or MRI brain (cerebral metastases — present in <5% but highest mortality risk), CT abdomen and pelvis (hepatic, splenic metastases), and repeat pelvic ultrasound. FIGO anatomical staging (I–IV) and prognostic scoring (FIGO/WHO risk score based on age, antecedent pregnancy, interval from pregnancy, HCG level, largest tumor size, number and site of metastases, prior chemotherapy) stratify patients into low risk (score ≤6) and high risk (score ≥7) — this guides chemotherapy intensity.

GTN treatment is based on FIGO risk score and follows RCOG, ESMO, and NCCN guidelines. Low-risk GTN (FIGO score ≤6, no metastases or lung-only metastases): single-agent chemotherapy is curative in approximately 70–80% of patients. First-line is intramuscular methotrexate 50 mg/m² on days 1, 3, 5, 7, alternating with folinic acid rescue on days 2, 4, 6, 8 (8-day regimen), or methotrexate 1 mg/kg IM on days 1, 3, 5, 7 (4-day regimen). Actinomycin D is used for methotrexate resistance. Chemotherapy is continued for 3 consolidation cycles after beta-HCG normalization. Hysterectomy may be curative for non-metastatic GTN in women who have completed childbearing, or for PSTT/ETT. High-risk GTN (FIGO score ≥7, non-lung or combined metastases): multi-agent chemotherapy is standard. EMA-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) achieves cure in approximately 85–90% of high-risk patients. EMA-CE (etoposide replacing cyclophosphamide/vincristine) or BEP (bleomycin, etoposide, cisplatin) are used for EMA-CO resistance. Cerebral metastases are treated with whole-brain radiotherapy (30 Gy) combined with EMA-CO with methotrexate dose-intensification. After beta-HCG normalization, 6–8 consolidation cycles minimize relapse risk. Surgical resection of chemotherapy-resistant isolated metastases is used in salvage settings. PSTT and ETT are managed primarily with surgery (hysterectomy) due to relative chemoresistance.

Gestational trophoblastic neoplasia (GTN) is one of the most curable malignancies in all of oncology — even with metastatic disease — because of its exquisite chemosensitivity and the availability of an extremely reliable tumor marker (beta-HCG) that enables precise monitoring of treatment response, residual disease, and cure. Low-risk GTN (FIGO/WHO score 0–6) — comprising the majority of cases — achieves cure rates approaching 100% with single-agent methotrexate or actinomycin-D chemotherapy. High-risk GTN (score ≥7, including high-risk choriocarcinoma and stage IV disease) treated with EMA-CO (etoposide, methotrexate, actinomycin-D, cyclophosphamide, vincristine) achieves cure rates of 85–90%, and salvage regimens (EMA-EP, TP-TE, BEP) rescue the majority of EMA-CO failures. Ultra-high-risk GTN (stage IV or WHO score ≥13) benefits from induction low-dose etoposide-cisplatin before standard EMA-CO to reduce the risk of early respiratory failure from massive tumor lysis. Placental site trophoblastic tumor (PSTT) and epithelioid trophoblastic tumor (ETT) are less chemosensitive than choriocarcinoma — they are primarily managed surgically and have poorer outcomes when metastatic. Fertility preservation is achieved in more than 95% of patients treated for GTN — subsequent pregnancies after treatment are not associated with increased miscarriage or congenital abnormality risk, unlike systemic chemotherapy used for other malignancies. Cure is defined as three consecutive normal weekly beta-HCG levels after completing chemotherapy. Long-term survivors have normal fertility and life expectancy.

After suction evacuation of a hydatidiform mole, all patients are registered for beta-HCG surveillance in GTD trophoblastic disease centers (Charing Cross Hospital UK model, or equivalent national programs). Weekly beta-HCG is measured until normalization, then monthly for 6 months (partial mole) or 12 months (complete mole). Pregnancy should be avoided during the surveillance period — oral contraceptive pills or condoms are recommended (contraceptive pills do not increase GTN risk). After GTN diagnosis and treatment, beta-HCG surveillance continues at 4–8-week intervals for 1–2 years. Subsequent pregnancy is generally safe and does not increase GTN relapse risk — the risk of another molar pregnancy in a future pregnancy is approximately 1–2% after one complete mole. Fertility is preserved in >95% of patients treated for GTN. Genetic counseling regarding the recurrent molar pregnancy syndrome (NLRP7, KHDC3L gene mutations causing biparental complete moles) should be offered to women with two or more molar pregnancies.

Any woman who experiences irregular vaginal bleeding — particularly after a recent pregnancy, miscarriage, or molar evacuation — and whose beta-HCG does not fall as expected or rises again should be evaluated urgently for GTN. Women with hemoptysis, new neurological symptoms (headache, seizures, visual disturbance), or intraperitoneal bleeding following any type of pregnancy require emergency evaluation with beta-HCG measurement and imaging to exclude choriocarcinoma with metastatic disease. A woman of reproductive age presenting with a lung nodule, unexplained pleural effusion, or cerebral lesion — particularly without prior smoking history or obvious primary tumor — should have beta-HCG measured to exclude choriocarcinoma, which may arise after a forgotten or remote pregnancy. Women who develop chest pain or hemoptysis and have a remote history of miscarriage, ectopic pregnancy, or term delivery should not have GTN excluded without a serum beta-HCG. All cases of suspected GTN must be referred urgently to a specialist GTD center — treatment decisions require expertise in FIGO scoring and precise beta-HCG-guided chemotherapy.